ONBOARD AND UNDER YOUR CONTROL

DEXTENZA is an advancement in steroid treatment

Resorbable, so no need for removal1

Insert can be removed via saline irrigation or manual expression, if necessary1

Physicians rated DEXTENZA as easy-to-insert2,3*
Designed to deliver a tapered dose4
Contains fluorescein for visualization1
No additional components or assembly required1

DEXTENZA is preservative-free1

Consider the preservative load

Preservatives (eg, benzalkonium chloride) in some topical drops can cause changes in the ocular surface, which may lead to inflammation and damage to the tear film.5

*73.6% of physicians in Study 1, 76.4% in Study 2, and 79.6% in Study 3, for the treatment of ocular inflammation and pain following ophthalmic surgery, rated DEXTENZA as easy-to-insert.2,3

A graphic showing tweezers.

ONBOARD USING A NOVEL TECHNOLOGY

DEXTENZA is dexamethasone delivered via ELUTYXTM technology1-3

Showing a graphic demonstrating DEXTENZA activating in the canaliculus following insertion

Activates

With moisture and swells to fit securely in the canaliculus
prev-btn
next-btn
Showing a graphic depicting the DEXTENZA insert releasing dexamethasone

Releases

Dexamethasone for up to 30 days
prev-btn
next-btn
Showing a graphic depicting how the DEXTENZA insert has cleared from the canaliculus

Resorbs

Slowly through the course of treatment and clears via the nasolacrimal duct
prev-btn
next-btn
Showing the Dextenza insertion graphic, an example of what the Dextenza product looks like.

DEXTENZA is designed to:

  • Allow for physician-controlled administration4
  • Provide sustained coverage for up to 30 days1

Positive Patient Experience In The Operating Room

Patients reported highly favorable outcomes in comfort, convenience, and satisfaction6

Survey results based on the responses from 201 DEXTENZA patients who participated in the third Phase 3 Study for inflammation and pain following ophthalmic surgery.6†

described the insert as comfortable

96% of patients described the insert as comfortable [Slightly Comfortable 6 ( 3.0%), Somewhat Comfortable 15 ( 7.5%), Very Comfortable 70 ( 34.8%), Extremely Comfortable 107 ( 53.2%)]

described the insert as convenient

97% of patients described the insert as convenient [Slightly Convenient 2 ( 1.0%), Somewhat Convenient 12 ( 6.0%), Very Convenient 58 ( 28.9%) 89 ( 43.0%), Extremely Convenient 124 ( 61.7%)]

were satisfied
with the insert

93% of patients were satisfied with the insert [Slightly Satisfied 8 ( 4.0%), Somewhat Satisfied 16 ( 8.0%) 31, Very Satisfied 58 ( 28.9%), Extremely Satisfied 113 ( 56.2%)]

were likely to request the insert for future treatment

93% were likely to request the insert for future treatment [Slightly Likely 9 ( 4.5%), Somewhat Likely 18 ( 9.0%), Very Likely 48 ( 23.9%), Extremely Likely 121 ( 60.2%)]

Represents users who felt extremely positive about the survey question.

Extremely

Represents users who felt very positive about the survey question.

Very

Represents users who felt somewhat positive about the survey question.

Somewhat

Study limitations7

  • Qualitative written survey (Questions not validated)
  • Relied on recall in an elderly population

†Intent-to-treat population.

How To Order

References: 1. DEXTENZA [package insert). Bedford, MA: Ocular Therapeutix, Inc: 2021. 2. Walters T, et al. J Clin Exp Ophthalmol. 2016;7(4): 1-11. 3. Tyson S. et al. J Cataract Refract Surg. 2019; 45:204–212 [erratum in: 2019;45(6):895]. 4. Sawhney AS, et al, Inventors; Incept, LLC, Assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013. 5. Baudouin C, et al. Prog Retin Eye Res. 2010;29(4):312-334. 6. Data on file 00837. Ocular Therapeutix, Inc. 7. Noecker RJ, et al. Evaluating the physician and patient experience of a dexamethasone insert (0.4 mg) in patients having cataract surgery. Presented at: American Society of Cataract and Refractive Surgery Annual Meeting. April 16, 2018; Washington, DC.

  open
  close

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

WARNINGS AND PRECAUTIONS

Intraocular Pressure Increase – Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Bacterial Infections – Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Viral Infections – Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections – Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Delayed Healing – Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Other Potential Corticosteroid Complications – The initial prescription and renewal of medication order of DEXTENZA should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

ADVERSE REACTIONS

Ocular Inflammation and Pain Following Ophthalmic Surgery
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%), intraocular pressure increased (6%), visual acuity reduced (2%), cystoid macular edema (1%), corneal edema (1%), eye pain (1%), and conjunctival hyperemia (1%). The most common non-ocular adverse reaction was headache (1%).

Itching Associated with Allergic Conjunctivitis
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: intraocular pressure increased (3%), lacrimation increased (1%), eye discharge (1%), and visual acuity reduced (1%). The most common non-ocular adverse reaction was headache (1%).

INDICATIONS

DEXTENZA is a corticosteroid indicated for:

  • The treatment of ocular inflammation and pain following ophthalmic surgery.
  • The treatment of ocular itching associated with allergic conjunctivitis.

Please see full Prescribing Information.